XOMA

XOMA Royalty Corp

Add to Watchlist

Advanced Chart

25.650

-0.82(-3.098%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

27.215

Open

26.500

VWAP

Vol

21.95K

Mkt Cap

306.95M

Low

25.630

Amount

EV/EBITDA(TTM)

41.08

Total Shares

11.64M

337.80M

EV/OCF(TTM)

P/S(TTM)

9.05

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others. The Company also acquires milestone and royalty revenue streams on late-stage or commercial assets.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

9.39M

-15.32%

9.92M

+37.87%

10.98M

+26.03%

Estimates Revision

The market is revising Upward the revenue expectations for XOMA Royalty Corporation (XOMA) for FY2025, with the revenue forecasts being adjusted by 4.77% over the past three months. During the same period, the stock price has changed by 6.70%.

Revenue Estimates for FY2025

Revise Upward

+4.77%

In Past 3 Month

Stock Price

Go Up

+6.70%

In Past 3 Month

3 Analyst Rating

305.46% Upside

Wall Street analysts forecast XOMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XOMA is 104.00 USD with a low forecast of 104.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

305.46% Upside

Current: 25.650

Low

104.00

Averages

104.00

High

104.00

305.46% Upside

Current: 25.650

Low

104.00

Averages

104.00

High

104.00

Benchmark

Robert Wasserman

Strong Buy

Initiates

$35

2025-04-17

Reason

Benchmark

Robert Wasserman

Price Target

$35

2025-04-17

Initiates

Strong Buy

Reason

Benchmark analyst Robert Wasserman initiated coverage of Xoma with a Buy rating and $35 price target. Xoma has expanded its royalty aggregate business through acquisitions and internal growth over the past several years, notes the analyst, who expects the R&D pipeline and recently completed commercial asset acquisitions to continue to drive double digit revenue growth over the next several years.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$104

2025-03-28

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$104

2025-03-28

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$104

2025-03-19

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$104

2025-03-19

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$123 → $104

2025-02-03

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$123 → $104

2025-02-03

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$123

2025-01-07

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$123

2025-01-07

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$123

2024-12-13

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$123

2024-12-13

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for XOMA Royalty Corp (XOMA.O) is 0.00, compared to its 5-year average forward P/E of -216.29. For a more detailed relative valuation and DCF analysis to assess XOMA Royalty Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-216.29

Current PE

0.00

Overvalued PE

825.66

Undervalued PE

-1258.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-40.24

Current EV/EBITDA

49.01

Overvalued EV/EBITDA

320.84

Undervalued EV/EBITDA

-401.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

18.94

Current PS

6.57

Overvalued PS

34.34

Undervalued PS

3.54

Financials

Annual

Quarterly

FY2025Q1

YoY :

+967.92%

15.91M

Total Revenue

FY2025Q1

YoY :

-184.65%

5.93M

Operating Profit

FY2025Q1

YoY :

-127.54%

2.37M

Net Income after Tax

FY2025Q1

YoY :

-104.65%

0.04

EPS - Diluted

FY2025Q1

YoY :

-144.28%

2.20M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-80.09%

-62.42

FCF Margin - %

FY2025Q1

YoY :

-102.58%

14.88

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

11.6M

USD

3-6

Months

0.0

USD

6-9

Months

17.9M

USD

0-12

Months

0.0

USD

Bought

0-3

50.8K

USD

Months

3-6

960.0K

USD

Months

6-9

21.8K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

392.7K

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

2.3K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

11.6M

USD

3-6

Months

0.0

USD

6-9

Months

17.9M

USD

0-12

Months

0.0

USD

Bought

0-3

50.8K

USD

Months

3-6

960.0K

USD

Months

6-9

21.8K

USD

Months

0-12

0.0

USD

Months

XOMA News & Events

Events Timeline

2025-07-14 (ET)

2025-07-14

08:03:59

XenoTherapeutics to acquire Essa Pharma

2025-06-27 (ET)

2025-06-27

07:36:08

Xoma to acquire Turnstone Biologics for $0.34 in cash per share

2025-05-27 (ET)

2025-05-27

08:21:39

Xoma purchases mezagitamab royalty, milestone rights for up to $30M

News

8.5

07-14PRnewswire

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

8.5

06-27NASDAQ.COM

XOMA To Acquire Turnstone Biologics For $0.34/Shr Plus Contingent Value Right

8.5

06-27Newsfilter

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

People Also Watch

ChoiceOne Financial Services Inc

Ponce Financial Group Inc

SIM Acquisition I Corp

USD

0.00%

TTSH

Tile Shop Holdings Inc

Orion Group Holdings Inc

Taysha Gene Therapies Inc

FAQ

What is XOMA Royalty Corp (XOMA) stock price today?

The current price of XOMA is 25.65 USD — it has decreased -3.1 % in the last trading day.

XOMA

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

XOMA News & Events

Events Timeline

News

People Also Watch

FAQ

What is XOMA Royalty Corp (XOMA) stock price today?

What is XOMA Royalty Corp (XOMA)'s business?

What is the price predicton of XOMA Stock?

What is XOMA Royalty Corp (XOMA)'s revenue for the last quarter?

What is XOMA Royalty Corp (XOMA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for XOMA Royalty Corp (XOMA)'s fundamentals?

How many employees does XOMA Royalty Corp (XOMA). have?

What is XOMA Royalty Corp (XOMA) market cap?